20-Week Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and Anemia
Public ClinicalTrials.gov record NCT01906489. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Assess the Pharmacodynamic Response, Safety, and Tolerability to 20 Weeks of Oral Dosing of AKB-6548 in Participants With Anemia Secondary to Chronic Kidney Disease (CKD), GFR Categories G3a-G5 (Stages 3, 4, AND 5) (Pre-Dialysis)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the hemoglobin response (efficacy), safety, and tolerability of orally administered AKB-6548 in participants with Chronic Kidney Disease (pre-dialysis) with anemia with dosing for 20 weeks.
Study identification
- NCT ID
- NCT01906489
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 210 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 82 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 22, 2013
- Primary completion
- Sep 2, 2014
- Completion
- Sep 2, 2014
- Last update posted
- Jul 20, 2022
2013 – 2014
United States locations
- U.S. sites
- 47
- U.S. states
- 19
- U.S. cities
- 47
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Glendale | Arizona | — | — |
| Not listed | Tucson | Arizona | — | — |
| Not listed | Azusa | California | — | — |
| Not listed | Chula Vista | California | — | — |
| Not listed | Downey | California | — | — |
| Not listed | El Centro | California | — | — |
| Not listed | La Mesa | California | — | — |
| Not listed | Long Beach | California | — | — |
| Not listed | Riverside | California | — | — |
| Not listed | Sacramento | California | — | — |
| Not listed | San Diego | California | — | — |
| Not listed | Arvada | Colorado | — | — |
| Not listed | Westminster | Colorado | — | — |
| Not listed | Lauderdale Lakes | Florida | — | — |
| Not listed | Port Charlotte | Florida | — | — |
| Not listed | Tampa | Florida | — | — |
| Not listed | Augusta | Georgia | — | — |
| Not listed | Macon | Georgia | — | — |
| Not listed | Meridian | Idaho | — | — |
| Not listed | Evergreen Park | Illinois | — | — |
| Not listed | Lafayette | Louisiana | — | — |
| Not listed | Shreveport | Louisiana | — | — |
| Not listed | Detroit | Michigan | — | — |
| Not listed | Lansing | Michigan | — | — |
| Not listed | Petoskey | Michigan | — | — |
| Not listed | Pontiac | Michigan | — | — |
| Not listed | Farmington | Missouri | — | — |
| Not listed | Kansas City | Missouri | — | — |
| Not listed | Las Vegas | Nevada | — | — |
| Not listed | Albuquerque | New Mexico | — | — |
| Not listed | Flushing | New York | — | — |
| Not listed | Mineola | New York | — | — |
| Not listed | New Rochelle | New York | — | — |
| Not listed | Rosedale | New York | — | — |
| Not listed | Asheville | North Carolina | — | — |
| Not listed | Charlotte | North Carolina | — | — |
| Not listed | Rocky Mount | North Carolina | — | — |
| Not listed | Wilmington | North Carolina | — | — |
| Not listed | Cincinnati | Ohio | — | — |
| Not listed | Columbia | South Carolina | — | — |
| Not listed | Knoxville | Tennessee | — | — |
| Not listed | Arlington | Texas | — | — |
| Not listed | Austin | Texas | — | — |
| Not listed | Edinburg | Texas | — | — |
| Not listed | Houston | Texas | — | — |
| Not listed | San Antonio | Texas | — | — |
| Not listed | St. George | Utah | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01906489, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 20, 2022 · Synced Sep 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01906489 live on ClinicalTrials.gov.